ACTU Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Actuate Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.00 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ACTU | US Biotechs | US Market | |
|---|---|---|---|
| 7D | n/a | -0.3% | 2.6% |
| 1Y | n/a | 9.8% | 17.3% |
Return vs Industry: Insufficient data to determine how ACTU performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ACTU performed against the US Market.
Price Volatility
| ACTU volatility | |
|---|---|
| ACTU Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ACTU has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ACTU's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 10 | Dan Schmitt | actuatetherapeutics.com |
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Actuate Therapeutics, Inc. Fundamentals Summary
| ACTU fundamental statistics | |
|---|---|
| Market cap | US$172.49m |
| Earnings (TTM) | -US$27.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.2x
P/E RatioIs ACTU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACTU income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$27.77m |
| Earnings | -US$27.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -39.8% |
How did ACTU perform over the long term?
See historical performance and comparison